excluded. We also excluded patients with a present on admission secondary diagnosis of cholecystitis, appendicitis, peritonitis or abdominal infections.

Results. A total of 95,169 patients had a diagnosis of CAP with a culture or other test performed on the first day. A pathogen was detected in 15.4% of the patients, Among the pathogen positive patients, the mean age was 67 ± 16 years (range 18–89) and 52% were male. Thirty-four percent required ICU care and 8.4% died in the hospital. Almost all patients (99%) had at least one culture drawn, including blood (96%) and respiratory (51%) specimens. Bacteria were the most commonly detected pathogens. Among the Gram-positive bacteria, Streptococcus pneumoniae accounted for 2.2.2% followed by methicillin sensitive Staphylococcus aureus (MSSA) (14.8%) and methicillin-resistant S. aureus (7.9%). Among the Gram-negative bacteria, the most common organisms reported were Pseudomonas aeruginosa (5.9%), Escherichia coli (5.2%) and Hemophilus influenzae (5.3%). Mycoplasma pneumoniae was identified in 2.2%. Among viral pathogens, the most common were influenza virus (2.6%) and human rhinovirus (0.71%).

Conclusion. In a large US inpatient sample, a majority of patients with CAP had no microbial etiology identified by laboratory testing. Among the test positive patients, *S. pneumoniae* was the most common bacteria reported followed by MSSA and MRSA.

Disclosures. A. Deshpande, 3M: Investigator, Research support; Clorox: Investigator and Speaker's Bureau, Research grant and Speaker honorarium; Merck: Investigator and Speaker's Bureau, Research support. S. S. Richter, bioMerieux: Grant Investigator, Research grant; BD Diagnostics: Grant Investigator, Research grant; Roche: Grant Investigator, Research grant; Hologic: Grant Investigator, Research grant; Diasorin: Grant Investigator, Research grant; Accelerate: Grant Investigator, Research grant; Biofire: Grant Investigator, Research grant.

1470. Neurocognitively-Acting Potentially Inappropriate Medications, Alcohol, and Community-Acquired Pneumonia Among Patients with and Without HIV Christopher T. Rentsch, MPH 1,2,3 ; Janet P. Tate, MPH, ScD 1,3 ; Kirsha S. Gordon, PhD 1,3 ; Alice Tseng, Pharm D 4 ; Kristina M. Niehoff, Pharm D 5 ; Kristina A. Crothers, MD 6 ; E. Jennifer Edelman, MD 1,7 ; Amy C. Justice, MD, PhD 1,3 and VACS Project Team; 1 Yale School of Medicine, New Haven, Connecticut, 2 London School of Hygiene & Tropical Medicine, London, UK, 3 VA Connecticut Healthcare System, West Haven, Connecticut, 4 University Health Network, Toronto, ON, Canada, 5 Vanderbilt University, Nashville, Tennessee, 6 University of Washington, Seattle, Washington, 7 Yale School of Public Health, New Haven, Connecticut

Session: 147. Respiratory Infections: CAP *Friday, October 5, 2018: 12:30 PM*


Background. Alcohol interactions with neurocognitively-acting potentially inappropriate medications (NC-PIMs) may be more common, more harmful, and associated with lower levels of alcohol use among people living with HIV.

Methods. We conducted a nested case–control study using data from the Veterans Aging Cohort Study (2007–2015). Cases with community-acquired pneumonia (CAP) requiring hospitalization (n=6,716) were 1:5 matched to controls without CAP (n=33,253) at the time of event by age, sex, race, HIV status, baseline year, and duration of observation time. Index date was defined as CAP date for cases and match date for controls. Based on pharmacy data in the year prior to index date, NC-PIMs included receipt of at least one prescription of any duration for anticonvulsants, sedatives (including benzodiazepines), prescription opioids, antidepressants, antipsychotics, and muscle relaxants. Among HIV+, NC-PIMs exposure also included ritonavir (RTV), cobicistat (COBI), and efavirenz (EFV). Conditional logistic regression models were used to obtain adjusted odds ratios (OR) and 95% confidence intervals (CI) for NC-PIMs (any and count overall, and by class), alcohol use disorder (AUD) diagnoses in the year prior to index date, and their interaction adjusted for smoking status, VACS Index, steroids, vaccination status (influenza and pneumonia), hepatitis C, previous CAP, and various comorbidities.

Results. Among 39,989 patients, 17,161 (43%) were HIV+, 98% were male, and median age was 58 years. An increase in number of classes of NC-PIMs was associated with a 17% increase in the odds of CAP among HIV+ and uninfected, and this effect was augmented by contemporaneous AUD. Among HIV+, all classes of NC-PIMs apart from EFV were positively associated with CAP, most notably antipsychotics (OR 1.66, 95% CI 1.43–1.93). Among uninfected, the highest risk of CAP was associated with antipsychotics (OR 1.81, 95% CI 1.61–2.03) and anticonvulsants (OR 1.64, 95% CI 1.49–1.80). AUD positively interacted with sedatives, opioids, antidepressants, and muscle relaxants in both groups, and with RTV/COBI in HIV+ patients.


Conclusion. NC-PIMs, especially with concurrent AUD, are associated with increased CAP risk among those living with and without HIV.

Figure 1a. Adjusted associations and interactions between neurocognitively-acting potentially inappropriate medications (PIM) and alcohol use disorder (AUD) on the risk of community-acquired pneumonia, overall and by class of PIM



Adjusted for smoley status, VACS Index, steroids, vaccination status (influenza and pneumonia), hepatitis C, previous CAP, and various comorbidities including

Figure 1b. Adjusted associations and interactions between neurocognitively-acting potentially inappropriate medications (PIM) and alcohol use disorder (AUD) on the risk of community-acquired one umonia, overall and by class of PIM



plusted for smoking status, VACs index, steroids, vaccination status (influenza and pheumonia), nepatitis c, previous CAP, and various comorb Ironic obstructive pulmonary disease, asthma, coronary artery disease, congestive heart failure, ischemic stroke, and diabetes mellitus

Disclosures. All authors: No reported disclosures.

1471. Case Report: Andes Virus Hantavirus Pulmonary Syndrome in a Traveler Returning to the United States

David Bergamo, PA-C^{1,2}; Alfred Bacon, MD³; David Cohen, MD³; Paula Eggers, RN⁴; Aaron Kofman, MD⁵; Mary Choi, MD, MPH⁶ and John Klena, PhD⁶; ¹Infectious Disease Associates, Newark, Delaware, ²Christiana Care, Newark, Delaware, ³Christiana Care Health System, Newark, Delaware, ⁴Division of Public Health, Delaware Department of Health and Social Services, Dover, Delaware, ⁵Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, ⁶Viral Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, Georgia

Session: 148. Respiratory Infections: Miscellaneous *Friday, October 5, 2018: 12:30 PM*

Background. Andes virus (ANDV), a New World hantavirus, is transmitted to humans via contact with the long-tailed pygmy rice rat (Oligoryzomys longicaudatus) in Chile and Argentina. Unlike other hantaviruses, ANDV can be transmitted person-to-person. It has a case mortality rate of approximately 30%. Here we describe the first known, imported case of ANDV to the United States.

Methods. On January 9, 2018, a 29-year-old female with no significant past medical history returned to the United States from a 3-week group trip to Chile and Argentina. She did not receive vaccines or take prophylaxis. She visited Central California before returning to Delaware. January 19 she presented with fevers, vomiting, and extreme fatigue. Examination was remarkable for hypotension requiring fluid resuscitation and O saturation of 89% on room air. She described chest tightness. Influenza, community acquired pneumonia, and PE were considered. Sputum influenza A/B and RSV PCR were negative. Laboratories revealed hypoalbuminemia at 2.2 g/dL, thrombocytopenia at 61,000, and transaminitis with AST 342 and ALT 302. WBC was within normal range with maximum of 11,000. Computerized tomography (CT) of chest revealed bilateral lower lobe ground-glass opacities, pleural effusions, and pulmonary edema. She was started on antibiotics. Her symptoms continued. She developed blurred vision and peri-orbital edema. She required 3 L O, nasal cannula. Headaches, sweats, peripheral edema, and rales developed. Lyme, Ehrlichia, malaria studies, and blood cultures were negative. Acute EBV, CMV, HIV, hepatitis, and dengue serologies were also negative. Hantavirus serologies were obtained Day 4 of admission. She was discharged Day 6 after resolution of fever, hypoxia and thrombocytopenia.

Results. Hantavirus ELISA IgG and IgM were reported positive 4 days after discharge and testing at the CDC confirmed ANDV infection.

Conclusion. Hantavirus is prevalent in certain South American locales. It should be considered in all patients returning from Chile and Argentina with fever, shortness of breath, and thrombocytopenia. Early recognition of symptoms and hallmark laboratories can identify patients that may require advanced supportive measures to decrease overall mortality.

Disclosures. All authors: No reported disclosures.

1472. Antibiotic De-escalation Compared with Continued Empirical Treatment in Non-Ventilated Hospital-Acquired Pneumonia

Shaikha Alnaimi, PharmD¹; Timothy Rawson, MD² and Alison Holmes, MD³; ¹Pharmacy, Hamad Medical Corporation, Doha, Qatar, ²Imperial College London, London, UK, ³Department of Infectious Diseases & Immunity, Imperial College Healthcare NHS Trust, London, UK

Session: 148. Respiratory Infections: Miscellaneous *Friday, October 5, 2018: 12:30 PM*

Background. Antibiotic de-escalation is an important component of antimicrobial stewardship programs. Nosocomial pneumonia is the most common healthcare-associated infection with nonventilated hospital-acquired pneumonia (HAP) comprising the majority of cases. We aimed to compare antibiotic de-escalation with continued empirical treatment in terms of clinical outcomes in nonventilated HAP.

Methods. A retrospective cohort study was conducted including patients meeting the American Thoracic Society criteria for HAP. This compared de-escalated HAP patients to those continued on empirical treatment across three hospitals in West London over 3 months. The primary outcome was the length of stay (LOS), and secondary outcomes were duration of treatment and cost of hospital stay. Effects were adjusted for confounders using multivariate linear regression models.

Results. Eighty patients with HAP were identified. Overall, 22/80 (27.5%) had therapy de-escalated and 47/80 (58.8%) continued empirical treatment. A total of 58 patients survived and were included in the analysis, 20 in de-escalation and 38 in continued empirical treatment. Length of stay was shorter in de-escalation by -7.2 (95% CI -12.2, -3.0) days, P < 0.01, with an adjusted difference of -3.2 (95% CI -8.3, 1.9) days, P = 0.21. The duration of treatment was shorter in de-escalation by -3.4 (95% CI -5.8, -0.9) days, P < 0.01, with an adjusted difference of -2.6 (95% CI -5.2, 0.1) days, P = 0.06. The cost of hospital stay was lower in de-escalation by £-2, 907.37 (95% CI -4.865.31, -949.43), P < 0.01, with an adjusted difference of £-1,290.00 (95% CI -3.320.75, 740.74), P = 0.21.

Conclusion. In HAP, 27.5% of patients were de-escalated. There was no difference in LOS, duration of treatment, and cost of hospital stay between de-escalation and continued empirical treatment on adjustment for confounders. Future work should explore the relationship between de-escalation and antimicrobial resistance in HAP.

Disclosures. All authors: No reported disclosures.

This abstract has been withdrawn at the author's request.

1474. Etiology of Pulmonary Granulomas: How Common is Unsuspected Infection?

Barbara Alvarez, MD; Edward K. Chapnick, MD, FIDSA, FSHEA; Monica Ghitan, MD, FIDSA and Yu Shia Lin, MD¹; ¹Division of Infectious Diseases, Maimonides Medical Center, Brooklyn, New York

Session: 148. Respiratory Infections: Miscellaneous *Friday, October 5, 2018: 12:30 PM*

Background. Granulomatous inflammation of the lung may be due to mycobacterial or fungal infections, sarcoidosis or vasculitis. When lung biopsy is performed due to suspicion of neoplasm, cultures may not always be done. In these cases, it is often not possible to order microbiologic testing when the pathology report is completed. The purpose of this study was to investigate how often patients with pulmonary nodules, who underwent biopsy for suspected malignancy, simultaneously have specimens sent for culture to assess for an infectious etiology.

Methods. We retrospectively reviewed the pathology reports of 36 patients from 2014 to 2015 who underwent lung biopsy of pulmonary nodules that showed granulomatous inflammation.

Results. Thirty-six patients underwent lung biopsy of pulmonary nodules. One patient was excluded because their pathology report did not reveal any granuloma, resulting in a final sample size of 35 patients. Of these, eight (22.9%) patients simultaneously had specimens sent for mycobacterial and fungal cultures while the other 27 (77.1%) did not. Of the 27 patients who did not have specimens simultaneously sent for mycobacterial and fungal cultures, 17 (48.6% of the sample size) were diagnosed with lung cancer. The remaining 10 (28.6% of the sample size) patients did not have a definitive diagnosis because cultures were not sent for testing (Figure 1). Of the eight patients

with cultures sent for testing, two (25%) had pulmonary tuberculosis, four (50%) had nontuberculosis mycobacterium infections, and two (25%) had fungal infections (one was Cryptococcus and one had mixed Aspergillus and Penicillium) (Figure 2).

Conclusion. We conclude that pulmonary nodules may have an infectious etiology when biopsy is performed for a suspected malignancy. Specimens should routinely be sent for mycobacterial and fungal cultures regardless of presumptive diagnosis.

Figure 1:





Figure 2. (MTB, Mycobacterium tuberculosis; NTB, non-Mycobacterium tuberculosis)



Disclosures. All authors: No reported disclosures.

1475. Etiology and Outcome of Fever and Respiratory Distress in Adult Patients Presenting to Medical Emergency in a Tertiary Care Hospital in North India Vikas Suri, MBBS MD(MED)¹; Harshit R Rao, MBBS MD(MED)²; Ashish Bhalla, MBBS MD(MED)¹; Inderpaul Singh, MBS MD DM(PUL MED)²; Manisha Biswal, MBBS MD(Microbiology)³; Mini P Singh, MBBS MD(Microbiology)⁴; Kapil Goyal, MBBS MD(Microbiology)⁵ and Kamran Zaman, MBBS MD(Microbiology)⁶; ¹Internal Medicine, PGIMER Chandigarh, Chandigarh, India, ²Pulmonary Medicine, PGIMER Chandigarh, India, ³Medical Microbiology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India, ⁴Virology, PGIMER Chandigarh, Chandigarh, India, ⁵Microbiology(Virology), PGIMER Chandigarh, Chandigarh, India, ⁶Medical Microbiology, PGIMER Chandigarh, India, Chandigarh, Chandigarh, India, Chandigarh, Chandigarh, India, Chandigarh, Chandigarh, India, Chandigarh, India

Session: 148. Respiratory Infections: Miscellaneous *Friday, October 5, 2018: 12:30 PM*

 $\it Background.~$ To study the region-specific etiology and outcome in a dult patients with acute febrile illness and ARDS

 $\it Methods.$ Prospective observational study done among 102 adult patients admitted to medical emergency, PGIMER, during study interval of 18 months (January 2016 to June 2017), with acute febrile illness (oral temperature more 101°F for less than 14 days with no localising symptoms) and ARDS(acute onset respiratory distress within one week of fever or new/worsening respiratory symptoms with bilateral opacities on chest radiograph, symptoms not explained by cardiac failure or fluid overload with PaO_/FiO_2 ratio <300 with PEEP or CPAP >5 cm H_O).All patients were investigated for the etiology as per standard protocol for malaria, scrub typhus, Leptospira, enteric fever, dengue, H1N1 influenza. Patients were followed till discharge or 28th day whichever is longer

Results. Among the 102 patients recruited in the study, 41.2% were males and 58.8% were females. Mean age of presentation was 38.06+/-17.26 years. 46% of patients admitted during post monsoon season. 26.5% patients had succumbed to their illness. Cough (61.8%), hepatomegaly (50%), myalgia (50%), splenomegaly (30.3%),